A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Study sponsor: Nektar Therapeutics · NKTR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-05-06Actual
Enrollment · participants396Estimated
Source updated2026-08-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.